SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The FDA alignment on a single registrational trial and strong Phase 2a efficacy/tolerability data significantly de-risk AlloNK's path to market. Traders should watch for the official FDA minutes and initiation of the Phase 3 trial in H2 2026 as key catalysts. The stock may re-rate upward given the large refractory RA market opportunity and the off-the-shelf advantage over CAR-T.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.89
T+0 close · May 8, 2026 · via day close
Latest settled
+1.65%
T+60 · $11.07
Vs SPY
−3.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $10.89entry
  2. T+1 · 6mo ago −2.66%α −2.89% · $10.60
  3. T+5 · 6mo ago −1.93%α −3.39% · $10.68
  4. T+20 · 5mo ago −37.10%α −37.12% · $6.85
  5. T+60 · 3mo ago +1.65%α −3.19% · $11.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six months in its company-sponsored trial, and FDA alignment on a single registrational Phase 3 trial expected to start H2 2026. The data supports AlloNK's potential as an off-the-shelf deep B-cell depleting therapy with a favorable outpatient tolerability profile, de-risking the path to a BLA submission in 2029.

Key Facts

  • 71% ACR50 response at six months in company-sponsored Phase 2a basket trial (5 of 7 patients) in refractory RA.
  • FDA alignment on a single registrational Phase 3 trial for AlloNK in refractory RA, with ACR50 at six months as primary endpoint.
  • Phase 3 trial expected to enroll ~150 patients, randomized 2:1 AlloNK+rituximab vs rituximab alone, with crossover option.
  • No CRS, ICANS, or treatment discontinuations observed in autoimmune patients; tolerability supports outpatient community administration.
  • More than 70 autoimmune patients treated with AlloNK across >40 active clinical sites, mostly in community settings.
  • B-cell depletion observed uniformly by Day 13 in all 51 evaluable patients; B-cell reconstitution shows naïve/transitional predominance consistent with 'reset'.
  • Initial data in Sjögren disease (n=7 at 6 months) and systemic sclerosis (n=4 at 6 months) show consistent clinical improvements.
  • Artiva expects to initiate Phase 3 in H2 2026, report primary efficacy data in H2 2028, and submit BLA in 2029.
  • Artiva estimates 150,000-200,000 refractory RA patients in the U.S. who have failed ≥2 b/tsDMARDs, with only 11-19% ACR50 likelihood on current therapies.

Financial Impact

No financial data provided in press release; market cap ~$309M. Positive clinical data and FDA alignment likely to increase valuation if Phase 3 succeeds.

revenuemarket cap

Risk Factors

  • Phase 3 trial may fail to meet primary endpoint or show safety issues in a larger population.
  • FDA minutes from recent interaction could include requests for additional data or different trial design.
  • Competition from other deep B-cell depleting therapies (e.g., CAR-T, bispecifics) could limit market share.
  • Artiva will need additional financing to complete Phase 3 and BLA submission; dilution risk exists.
  • Pooled data from separate trials (company-sponsored and IIT) may not be directly comparable.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290957

Track record

33 reports on ARTV

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026